摘要
目的:观察参松养心胶囊联合茶碱缓释片治疗心律失常的临床疗效及安全性。方法:将60例心律失常患者随机分为2组各30例,对照组在西医常规治疗的基础上加用茶碱缓释片口服,观察组在对照组治疗的基础上联合参松养心胶囊治疗;疗程均为4周,观察2组临床疗效、心胸比、血压、心率、心律失常情况、心率变异性[全程每5 min NN节段的窦性RR间期标准差(SDANN)、全程连续窦性RR间期标准差(SDNN)、全程相邻RR之差的均方根(RMSSD)]等的变化情况。结果:总有效率观察组为93.33%,对照组为60.00%,2组比较,差异有统计学意义(P <0.05)。治疗后,2组患者心胸比(对照组除外)、收缩压、舒张压、心率均较治疗前降低(P <0.05);且观察组上述各项指标改善较对照组更显著(P <0.05)。治疗后,2组患者室性期前收缩、房性期前收缩、房室交界区性期前收缩次数均较治疗前显著降低(P <0.05),且观察组上述各项指标次数均低于对照组(P <0.05)。治疗后,2组心率变异性指标SDANN、SDNN、RMSSD值均较治疗前升高(P <0.05),且观察组上述指标升高较对照组更显著(P <0.05)。不良反应发生率观察组为3.33%,对照组为6.67%,2组比较,差异无统计学意义(P> 0.05)。结论:参松养心胶囊联合茶碱缓释片治疗心律失常临床疗效显著,疗效优于单纯西药治疗,值得临床推广应用。
Objective:To observe the clinical effect of Shensong Yangxin capsules combined with theophylline for arrhythmia and its safety. Methods:Divided 60 cases of patients with arrhythmia into two groups randomly,30 cases in each group. The control group was treated with routine western medicine and theophylline sustained release tablets orally. The observation group was additionally treated with Shensong Yangxin capsules based on the treatment of the control group. The treatment of both groups lasted for four weeks.Observe the clinical effect,cardiothoracic ratio,blood pressure,changes in heart rate,arrhythmia,heart rate variability including the standard deviation of the averages of normal-to-normal RR intervals of sinus in all 5-minute segments(SDANN),the standard deviation of normal-to-normal RR intervals(SDNN),the root mean square of successive differences between adjacent RR(RMSSD),and other changes in the two groups. Results:The total effective rate was 93.33% in the observation group and 60.00% in the control group,the difference being significant(P < 0.05). After treatment,the cardiothoracic ratio(except for that in the control group),systolic pressure,diastolic pressure and heart rate in the two groups were all decreased when compared with those before treatment(P < 0.05);the above indexes in the observation group were improved more significantly when compared with those in the control group(P < 0.05). After treatment,the times of premature ventricular contraction,premature atrial contraction and premature contraction of atrioventricular junction in the two groups were significantly decreased when compared with those before treatment(P < 0.05);the times of the above indexes in theobservation group were less than those in the control group(P < 0.05). After treatment,the levels of SDANN,SDNN and RMSSD in the two groups were increased when compared with those before treatment(P < 0.05);the above indexes in the observation group were improved more significantly when compared with those in the control group(P < 0.05). The incidence of adverse reactions was 3.33% in the observation group and 6.67% in the control group, the difference being not statistically significant(P > 0.05). Conclusion: The therapy of Shensong Yangxin capsules combined with theophylline for arrhythmia has more significant therapeutic effect than simple administration of western medicine,which is worthy of promotion and application.
引文
[1]黄家兴.参松养心胶囊治疗冠心病心律失常的临床观察[J].当代医学,2011,17(3):135-136.
[2]Lafuentelafuente C,Mouly S,Longástejero MA,et al.Antiar-rhythmic drugs for maintaining sinus rhythm after cardioversion ofa trial fibrillation:A systematic review of randomized controlledtrails[J].Arch Intern Med,2006,166(7):719-728.
[3]陈国伟,顾菊康,陈灏珠.心血管病诊断治疗学[M].合肥:安徽科学技术出版社,2003:420-421.
[4]郑筱萸.中药新药临床研究指导原则(试行)[M].北京:中国医药科技出版社,2002:239-243.
[5]白艳荣.参松养心胶囊治疗心律失常的疗效观察[J].中西医结合心脑血管病杂志,2011,9(10):1170-1171.
[6]牛丽珠,李佳和.心律失常采用参松养心胶囊联合胺碘酮治疗的临床效果观察[J].中国医药指南,2014(32):274-277.
[7]郭刚.参松养心胶囊治疗冠心病心律失常的临床效果分析[J].慢性病学杂志,2015,16(5):559-560.
[8]熊宇.参松养心胶囊联合西药治疗冠心病心律失常的疗效观察[J].中西医结合心血管病电子杂志,2016,4(14):128-129.